DeepMed Research

German Cancer Research Center

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1964-01-01

Employees: 1K

Market Cap: -

Website: http://www.dkfz.de

Clinical Trials

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Terminated

Conditions: CYP3A Inhibitor
Pancreatic Cancer
Pancreatic Adenocarcinoma
Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasm

Interventions: Drug: Cobicistat Oral Tablet
Drug: Gemcitabin
Drug: Nab paclitaxel

First Posted Date: 2022-08-10

Last Posted Date: 2025-03-25

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 6

Registration Number: NCT05494866

Locations: 🇩🇪
University Hospital Heidelberg, Heidelberg, BW, Germany

A Longitudinal Study to Investigate and Develop a Patient-centered and Effective Fatigue Screening

Active, not recruiting

Conditions: Cancer-related Fatigue

First Posted Date: 2022-07-07

Last Posted Date: 2025-03-26

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 300

Registration Number: NCT05448573

Locations: 🇩🇪
German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2

Recruiting

Conditions: Early-stage Breast Cancer

Interventions: Drug: Atezolizumab 1200 mg in 20 ML Injection
Drug: Trastuzumab/pertuzumab
Drug: Ipatasertib
Drug: Olaparib
Drug: Sacituzumab govitecan
Drug: Inavolisib

First Posted Date: 2022-04-18

Last Posted Date: 2025-03-20

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 240

Registration Number: NCT05332561

Locations: 🇩🇪
National Center for Tumor Diseases, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪
Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
🇩🇪
Universitätsklinikum Augsburg, Augsburg, Bayern, Germany

and more 6 locations

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: NK cells
Drug: Talazoparib 1 MG [Talzenna]

First Posted Date: 2022-04-08

Last Posted Date: 2024-04-05

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 54

Registration Number: NCT05319249

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers

Early Phase 1

Recruiting

Conditions: HPV

Interventions: Biological: Vaccination with PANHPVAX 10µg
Biological: Vaccination with PANHPVAX 100µg
Biological: Vaccination with PANHPVAX 40µg

First Posted Date: 2022-01-26

Last Posted Date: 2023-08-02

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 45

Registration Number: NCT05208710

Locations: 🇩🇪
University Hospital Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany

Longitudinal Investigation of Cancer-related Fatigue and Its Treatment (LIFT Project)

Active, not recruiting

Conditions: Cancer-related Fatigue

First Posted Date: 2021-06-10

Last Posted Date: 2025-03-26

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 1183

Registration Number: NCT04921644

Locations: 🇩🇪
German Cancer Research Center, Heidelberg, Germany

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Phase 1

Recruiting

Conditions: Newly Diagnosed H3-mutated Glioma

Interventions: Drug: Tecentriq 1200 MG in 20 ML Injection
Biological: H3K27M peptide vaccine
Other: Imiquimod (5%)

First Posted Date: 2021-03-22

Last Posted Date: 2024-04-05

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 15

Registration Number: NCT04808245

Locations: 🇩🇪
University Clinic Tuebingen, Neurological Clinic, Department of Neurology, Tuebingen, Baden-Wuerttemberg, Germany
🇩🇪
Clinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden, Dresden, Sachsen, Germany
🇩🇪
Department of Neurosurgery with Pediatric Neurosurgery, Berlin, Germany

and more 5 locations

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2

Completed

Conditions: Metastatic or Locally Advanced Malignancies

Interventions: Drug: Vemurafenib
Drug: Trastuzumab
Drug: Alectinib
Drug: Inavolisib
Drug: Ipatasertib
Drug: Cobimetinib
Drug: Pertuzumab
Drug: Atezolizumab

First Posted Date: 2020-09-16

Last Posted Date: 2025-01-08

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 72

Registration Number: NCT04551521

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany
🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany

and more 5 locations

Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

Phase 1

Terminated

Conditions: Lung Cancer Squamous Cell

Interventions: Drug: CC-1 and Toczilizumab

First Posted Date: 2020-08-03

Last Posted Date: 2025-04-23

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 3

Registration Number: NCT04496674

Locations: 🇩🇪
Robert Bosch Centrum für Tumorerkrankungen, Stuttgart, BW, Germany
🇩🇪
University Hospital Tuebingen, CCU Translational Immunology, Tuebingen, Bw, Germany

Afatinib in Advanced NRG1-Rearranged Malignancies

Phase 2

Completed

Conditions: Metastatic and Locally Advanced NRG1-rearranged Malignancies

Interventions: Drug: Afatinib 40 MG

First Posted Date: 2020-06-01

Last Posted Date: 2024-04-05

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 3

Registration Number: NCT04410653

Locations: 🇩🇪
NCT Dresden, Dresden, Germany
🇩🇪
NCT Heidelberg, Heidelberg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy